Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 8529 | 1.455 |
09:34 ET | 6287 | 1.45 |
09:36 ET | 571 | 1.4505 |
09:38 ET | 900 | 1.445 |
09:39 ET | 7130 | 1.455 |
09:41 ET | 100 | 1.455 |
09:43 ET | 5642 | 1.45 |
09:45 ET | 3158 | 1.45 |
09:48 ET | 207 | 1.455 |
09:50 ET | 1186 | 1.45 |
09:52 ET | 11786 | 1.44 |
09:54 ET | 956 | 1.445 |
09:56 ET | 2957 | 1.448 |
09:57 ET | 1499 | 1.4511 |
09:59 ET | 500 | 1.46 |
10:01 ET | 400 | 1.46 |
10:03 ET | 100 | 1.46 |
10:06 ET | 1700 | 1.46 |
10:10 ET | 3394 | 1.46 |
10:12 ET | 8720 | 1.46 |
10:14 ET | 12705 | 1.46 |
10:15 ET | 600 | 1.4603 |
10:17 ET | 200 | 1.465 |
10:19 ET | 1500 | 1.47 |
10:21 ET | 3950 | 1.475 |
10:24 ET | 1235 | 1.4799 |
10:26 ET | 17157 | 1.465 |
10:28 ET | 100 | 1.465 |
10:30 ET | 4372 | 1.465 |
10:32 ET | 2739 | 1.46 |
10:33 ET | 300 | 1.46 |
10:35 ET | 5100 | 1.4699 |
10:37 ET | 6486 | 1.465 |
10:39 ET | 1100 | 1.46 |
10:42 ET | 100 | 1.46 |
10:44 ET | 7250 | 1.46 |
10:46 ET | 17285 | 1.4701 |
10:48 ET | 20307 | 1.455 |
10:51 ET | 400 | 1.45 |
10:53 ET | 800 | 1.455 |
10:55 ET | 5200 | 1.45 |
10:57 ET | 4018 | 1.445 |
11:00 ET | 100 | 1.445 |
11:02 ET | 9549 | 1.45 |
11:06 ET | 700 | 1.445 |
11:08 ET | 17114 | 1.435 |
11:09 ET | 100 | 1.435 |
11:11 ET | 10943 | 1.4301 |
11:13 ET | 2097 | 1.435 |
11:15 ET | 489 | 1.44 |
11:18 ET | 16674 | 1.44 |
11:20 ET | 417 | 1.432 |
11:22 ET | 10610 | 1.4487 |
11:24 ET | 3200 | 1.44 |
11:26 ET | 1100 | 1.44 |
11:27 ET | 10000 | 1.4408 |
11:29 ET | 19943 | 1.43 |
11:31 ET | 5503 | 1.445 |
11:33 ET | 200 | 1.445 |
11:36 ET | 17839 | 1.44 |
11:38 ET | 196181 | 1.43 |
11:40 ET | 8460 | 1.428 |
11:42 ET | 12038 | 1.43 |
11:44 ET | 400 | 1.43 |
11:45 ET | 250 | 1.4276 |
11:47 ET | 850 | 1.425 |
11:49 ET | 2041 | 1.4276 |
11:51 ET | 1719 | 1.425 |
11:54 ET | 1000 | 1.42 |
11:56 ET | 4250 | 1.42 |
11:58 ET | 885 | 1.42 |
12:00 ET | 730 | 1.425 |
12:02 ET | 720 | 1.425 |
12:03 ET | 19874 | 1.42 |
12:05 ET | 1100 | 1.42 |
12:07 ET | 100 | 1.42 |
12:09 ET | 12079 | 1.425 |
12:12 ET | 743 | 1.425 |
12:14 ET | 72982 | 1.425 |
12:16 ET | 4380 | 1.425 |
12:18 ET | 400 | 1.42 |
12:20 ET | 1300 | 1.425 |
12:21 ET | 1617 | 1.42 |
12:23 ET | 1400 | 1.42 |
12:25 ET | 228902 | 1.39 |
12:27 ET | 16965 | 1.4 |
12:30 ET | 3549 | 1.4054 |
12:32 ET | 19842 | 1.41 |
12:36 ET | 1000 | 1.415 |
12:38 ET | 26940 | 1.42 |
12:39 ET | 1350 | 1.415 |
12:41 ET | 5954 | 1.425 |
12:43 ET | 300 | 1.425 |
12:45 ET | 100 | 1.43 |
12:50 ET | 100 | 1.43 |
12:52 ET | 700 | 1.424 |
12:54 ET | 200 | 1.43 |
12:56 ET | 1600 | 1.43 |
12:59 ET | 100 | 1.43 |
01:03 ET | 120 | 1.425 |
01:06 ET | 235 | 1.43 |
01:08 ET | 1600 | 1.4295 |
01:10 ET | 1000 | 1.425 |
01:12 ET | 4500 | 1.425 |
01:14 ET | 12400 | 1.42 |
01:15 ET | 10200 | 1.42 |
01:17 ET | 19989 | 1.415 |
01:19 ET | 100 | 1.415 |
01:21 ET | 5200 | 1.4101 |
01:24 ET | 6000 | 1.42 |
01:26 ET | 200 | 1.42 |
01:28 ET | 5000 | 1.415 |
01:30 ET | 5400 | 1.415 |
01:32 ET | 5340 | 1.42 |
01:33 ET | 2000 | 1.4199 |
01:35 ET | 5052 | 1.415 |
01:37 ET | 5500 | 1.415 |
01:39 ET | 47690 | 1.415 |
01:42 ET | 27705 | 1.4099 |
01:44 ET | 3800 | 1.405 |
01:46 ET | 19668 | 1.405 |
01:48 ET | 3674 | 1.4 |
01:50 ET | 1510 | 1.405 |
01:51 ET | 400 | 1.405 |
01:53 ET | 13483 | 1.3999 |
01:55 ET | 3600 | 1.395 |
01:57 ET | 350 | 1.3999 |
02:00 ET | 350 | 1.4 |
02:02 ET | 1349 | 1.405 |
02:04 ET | 5400 | 1.4001 |
02:06 ET | 11893 | 1.4 |
02:08 ET | 7843 | 1.395 |
02:09 ET | 100 | 1.4 |
02:13 ET | 700 | 1.4 |
02:15 ET | 6300 | 1.4 |
02:20 ET | 100 | 1.4 |
02:22 ET | 5600 | 1.395 |
02:24 ET | 54259 | 1.385 |
02:26 ET | 2100 | 1.385 |
02:27 ET | 700 | 1.385 |
02:29 ET | 39222 | 1.39 |
02:31 ET | 4376 | 1.384 |
02:33 ET | 400 | 1.39 |
02:38 ET | 1234 | 1.38 |
02:40 ET | 6845 | 1.39 |
02:42 ET | 100 | 1.3883 |
02:44 ET | 3072 | 1.39 |
02:45 ET | 3350 | 1.39 |
02:47 ET | 100 | 1.39 |
02:49 ET | 3914 | 1.385 |
02:51 ET | 426 | 1.39 |
02:54 ET | 661 | 1.385 |
02:56 ET | 2944 | 1.38 |
02:58 ET | 200 | 1.38 |
03:00 ET | 2692 | 1.384 |
03:02 ET | 22103 | 1.39 |
03:03 ET | 450 | 1.3917 |
03:05 ET | 7636 | 1.3901 |
03:07 ET | 300 | 1.4 |
03:09 ET | 100 | 1.39 |
03:12 ET | 300 | 1.4 |
03:14 ET | 100 | 1.395 |
03:16 ET | 1750 | 1.3999 |
03:18 ET | 2773 | 1.4 |
03:20 ET | 2900 | 1.394 |
03:21 ET | 700 | 1.395 |
03:23 ET | 3300 | 1.395 |
03:25 ET | 11980 | 1.395 |
03:27 ET | 7391 | 1.395 |
03:30 ET | 4973 | 1.39 |
03:32 ET | 454 | 1.395 |
03:34 ET | 1200 | 1.395 |
03:36 ET | 455 | 1.395 |
03:39 ET | 400 | 1.394 |
03:41 ET | 382 | 1.395 |
03:43 ET | 500 | 1.395 |
03:45 ET | 7572 | 1.39 |
03:48 ET | 24298 | 1.395 |
03:50 ET | 6525 | 1.385 |
03:52 ET | 4488 | 1.385 |
03:54 ET | 1200 | 1.385 |
03:56 ET | 23841 | 1.38 |
03:57 ET | 30859 | 1.385 |
03:59 ET | 32434 | 1.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 113.8M | 7.0x | --- |
Spero Therapeutics Inc | 74.0M | 3.2x | --- |
2Seventy Bio Inc | 210.2M | -0.9x | --- |
Rigel Pharmaceuticals Inc | 170.8M | -8.4x | --- |
G1 Therapeutics Inc | 156.3M | -4.5x | --- |
Seres Therapeutics Inc | 107.6M | -1.2x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $113.8M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 7.0x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | 6.1x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.